-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group’s Guolong Pharmaceutical Receives Approval for Vitamin A Palmitate API
Category:
发布时间：2025-11-27
【概要描述】
On November 26, Vitamin A Palmitate developed by Hebei Guolong Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed dosage forms. To date, the Group’s portfolio includes 88 API products, 39 of which are manufactured by Guolong Pharmaceutical.
On November 26, Vitamin A Palmitate, developed by Hebei Guolong Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed dosage forms. To date, the Group has a total of 88 API products, 39 of which are manufactured by Guolong Pharmaceutical.
According to available information, vitamin A palmitate is classified as a vitamin and nutritional drug.
In recent years, the Group has closely aligned its strategies with industry development and market demand, continuously deepening its integrated innovation framework of “APIs + formulations.” This approach has effectively promoted the specialization of product portfolios, the consolidation of industrial clusters, the greening of manufacturing processes, and the diversification of distribution channels, thereby achieving deep integration and synergistic collaboration between the Group’s formulation and API businesses. As a result, the Group has secured robust dual-engine momentum to accelerate its growth.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091